--- title: "Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026 | CDIO Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/294968961.md" description: "Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) announced it will host an investor conference call on Thursday, August 20, 2026, at 3 p.m. Central Time. The call will cover the company's precision molecular approach to cardiovascular disease prevention and detection, updates on tests Epi+Gen CHD™ and PrecisionCHD™, reimbursement progress, and strategic growth initiatives." datetime: "2026-08-05T04:35:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294968961.md) - [en](https://longbridge.com/en/news/294968961.md) - [zh-HK](https://longbridge.com/zh-HK/news/294968961.md) generator: "portal-rs" --- # Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026 | CDIO Stock News See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google Add on Google CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Thursday, August 20, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company’s precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, ongoing and planned studies, reimbursement progress, and strategic growth initiatives. **Webcast and Conference Call Details** **Date:** Thursday, August 20, 2026 **Time:** 3 p.m. Central Time **Webcast:** https://www.cstproxy.com/cardiodiagnosticsinc/investorday/2026/aug/ To access the conference call by telephone, U.S. and Canada-based callers should dial 1 800-450-7155 (toll-free), and callers from outside the U.S. and Canada should dial +1 857-999-9155 (standard rates apply). Participants should use the passcode provided below to join. **Passcode:** 4543643# A replay of the webcast will be available via the webcast link above following the conclusion of the call. **About Cardio Diagnostics** Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine ("Core Technology") for cardiovascular disease. For more information, please visit https://cdio.ai/. **Forward-Looking Statements** Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will," "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, and dependence on results as discussed in the Annual Report on Form 10-K for the period ended December 31, 2025, under the heading "Risk Factors" in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20260805019123/en/ **Investors** Investor Relations 855-226-9991 investors@cdio.ai Source: Cardio Diagnostics Holdings, Inc. ### Related Stocks - [CDIO.US](https://longbridge.com/en/quote/CDIO.US.md) - [CDIOW.US](https://longbridge.com/en/quote/CDIOW.US.md) ## Related News & Research - [Silicon Valley wealth managers say elite tech workers are making these 5 money moves as AI mania continues](https://longbridge.com/en/news/297398623.md) - [5 Ways AI is Transforming International Outsourcing for Small Businesses with Big Growth Ambitions](https://longbridge.com/en/news/297768665.md) - [AI Was Supposed to Kill Wix. Google Just Gave It a Way to Fight Back.](https://longbridge.com/en/news/297433684.md) - [Quadient to report first-half 2026 results, host webcast and call](https://longbridge.com/en/news/297743836.md) - [DWTX: Halneuron shows promise as a scalable, effective CINP therapy with strong Phase 2 results](https://longbridge.com/en/news/297686345.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**